Stereodivergent syntheses of altro and manno stereoisomers of 2-acetamido-1,2-dideoxynojirimycin by Fuente Cebrián, Àlex de la et al.
FULL PAPER    
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Alex de la Fuente,[a] Xavier Verdaguer,[a,b] Antoni Riera [a,b]* 
 
Abstract: A stereoselective synthesis of 2-acetamido-1,2-
dideoxyaltronojirimycin (8) and its manno epimer (9) is 
described. The synthetic approach is based on the key 
bicyclic carbamate 7, which is easily accessible in high 
enantiomeric purity and multigram scale by Sharpless 
Asymmetric Epoxidation of 1,4-pentadien-3-ol or 2,4-
pentadien-1-ol. This procedure completes an efficient 
stereodivergent approach to five isomers of 2-acetamido-
1,2-dideoxyiminosugars with high overall yields starting 
from the same key intermediate 7. The present approach is 
based on the stereoselective control of the sulphite ring-
opening with retention of configuration due to the 
anchimeric effect of the endocyclic amine. 
Introduction 
Carbohydrates are involved in a variety of metabolic 
processes. The inhibitors of the enzymes related to 
carbohydrate metabolism, such as glycosidases or glycosyl 
transferases, have potential activity in the treatment of 
several diseases, including diabetes, viral and bacterial 
infections and cancer. Iminosugars—saccharides in which 
the oxygen ring atom has been substituted by a nitrogen—
are potent glycosidase inhibitors, acting as mimics of the 
corresponding glycosidic substrates.1–2 Derivatization of 
iminosugars by modification of the nitrogen and the pseudo-
anomeric carbon has been widely reported.3 However, the 
introduction of other substituents, such as halogens or 
amines, to replace some of the hydroxyl groups of the 
skeleton is relatively uncommon and synthetically 
challenging.4 Iminosugars in which an acetamido moiety 
replaces a hydroxyl group have received considerable 
attention in recent years due to their high selectivity for 
hexosaminidases, thus making them potentially useful for 
the treatment of lysosomal storage disorders,5 Alzheimer,6 
some cancers7 and other O-GlNAcase-related diseases8. The 
acetamido moiety is crucial for the high affinity of these 
compounds.9 Natural products of this family, such as 
siastatin B (1)10, nagstatin (2)11 and pochonicine (3),12 have 
been reported to show inhibitory activity that ranges from 
low micromolar to nanomolar. Among synthetic 
compounds,13 N-acetylglucosamine analogues such as 2-
acetamido-1,2-dideoxynojirimycin (4),14 and their galacto 
(5)15 or allo (6)16 isomers have received special attention 
(Figure 1). Most of the synthetic procedures for the 
synthesis of iminosugars described to date are based on the 
chiral pool starting from sugars or amino acids.17 
Conversely, our approach to iminosugar synthesis is based 
on the key precursor 7, which is easily accessible in high 
enantiomeric purity and multigram scale by Sharpless 
Asymmetric Epoxidation of 2,4-pentadien-1-ol18 or 1,4-
pentadien-3-ol.19a Carbamate 7 is a versatile intermediate 
that has been widely used for the synthesis of several 
carbohydrate-related compounds.19 Following this approach 
we have reported efficient stereoselective procedures to 
obtain (2S)-2-acetamido iminosugars 4, 5 and 6.14f,16 In our 
previous work, the (S) configuration of the acetamide in 
position 2 was secured by substitution reactions that took 
place with complete inversion of configuration.  
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Figure 1. Natural and synthetic examples of acetamido 
iminosugars. 
 
Herein we describe a new approach to obtain the previously 
unknown 2-acetamido-1,2-dideoxyaltronojirimycin (8) and 
its manno epimer (9), both with the (R) configuration in 
position 2 (Figure 2). To this end, we have taken advantage 
of the anchimeric effect of the nitrogen ring atom to perform 
substitution reactions with retention of configuration. These 
methodologies, which are short and give a high overall yield, 
have given access to a basic scaffold that can be easily 
modified to afford inhibitors with better drug-like properties. 
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Figure  2.  Stereodivergent  approach  to  2‐acetamido‐1,2‐
dideoxyiminosugars.  
Results and Discussion 
In our search to develop new methodologies through which 
to obtain (2R)-acetamido iminosugars, we envisaged 
exploiting the basic character of the nitrogen ring to 
generate a cyclic aziridinium cation susceptible to being 
opened by nitrogen nucleophiles, thereby leading to an 
overall retention of configuration process. Therefore, instead 
of having a carbamate protecting group during the ring-
opening of the sulphate with azide (Scheme 1, left), we 
considered that, that by using an alkyl protecting group, the 
nucleophilic attack would take place with retention of 
configuration via the aziridinium ion (Scheme 1, right). The 
anchimeric assistance of heterogeneous atoms in cyclic 
systems has previously been studied.20 Although this 
approach has been applied to ring expansion reactions in 
iminosugar synthesis by Cossy et al.21, to the best of our 
knowledge, it has not been used to open an epoxide, a 
sulphite or a sulphate with retention of configuration. 
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Scheme 1. Retrosynthetic analysis for 2S and 2R‐acetamido 
iminosugars. 
We started our syntheses by preparing multigram amounts 
of carbamate 7 using the procedure described. Optically 
pure 7, was first protected as the benzyl derivative 10 by 
treatment with BnBr/NaH. Hydrolysis of the 2-
oxazolidinone ring and protection of the corresponding 
amino alcohol with BnBr/NaH gave the fully benzyl 
protected derivative 11 in 87% yield. Dihydroxylation of 
this olefin using Sharpless conditions14f rendered the diol 12 
in 48% yield. The low yield was due to partial 
decomposition during chromatography (Scheme 2).  
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Scheme 2. a)BnBr, NaH, DMF, rt. b) NaOH 6M reflux, c) BnBr, NaH, 
DMF, rt; d) (DHQD)2Phal, K2OsO4∙2H2O, K3[Fe(CN)6], K2CO3, 
CH3SO2NH2, ACN:H2O 1:1, rt. 
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Sulphite 13 was obtained as a mixture of diastereoisomers in 
moderate yield by treatment of 12 with SOCl2/TEA. Its 
isolation was complex due to its tendency to decompose, so 
it was used directly in the next steps as a crude. Attempts to 
obtain the corresponding sulphate by oxidation of the 
sulphite or treatment of diol 12 with SO2Cl2/TEA22 were 
unsuccessful. Therefore, the ring-opening reactions of 13 
with NaN3 were widely explored (Scheme 3, Table 1). Due 
to the difficulty in handling the intermediates, the three 
reactions were done consecutively. The ratio of azido 
alcohols was the same as when the reaction was performed 
on pure 13, thereby demonstrating that the impurities of the 
first reactions have no effect on the opening reaction. After 
optimization of the reaction conditions, a 78:22 mixture of 
isomers was obtained in 47% yield in three steps. Separation 
of the two products by chromatography was achieved in a 
straightforward manner.  
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Scheme 3. a) (DHQD)2Phal, K2OsO4∙2H2O, K3[Fe(CN)6], K2CO3, 
CH3SO2NH2, ACN, H2O, rt; b) SOCl2/TEA; c) NaN3, acetone, H2O. 
The stereochemistry of 14/15 could not be determined by 
either NMR or by X-Ray diffraction studies. Therefore, the 
same chemical transformations were applied to both isomers 
in order to achieve the final 2R-acetamido iminosugars. The 
following reaction sequence was used: protection of the free 
hydroxyl by BnBr/NaH; hydrogenation of the azide 
catalyzed by Pd/C; in situ formation of the acetamide with 
Ac2O/pyridine; and cleavage of the benzyl groups by 
hydrogenolysis. In both cases, the final iminosugars were 
achieved in excellent yields (Scheme 4).  
Table 1. Conditions, overall yields and d.r of the conversion of 11 
into 14/15 (three steps). 
Entry NaN3/equiv T/ºC Yield / %] 14/15 
1[a] 3 50 71 54/47 
2 3 50 19 60/40 
3 2 rt 34 80/20 
4 1.2 35 47 78/22 
[a] Starting from pure 13 
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Scheme 4.  a) BnBr, NaH, DMF, rt; b) i) H2 (3 bar), Pd/C, EtOAc, ii) 
Ac2O, pyr; c) H2 (5 bar), Pd/C, HCl 1.25M, MeOH, rt. 
 
NMR analysis of the minor product allowed us to identify it 
as the already described 2-acetamido-1,2-
dideoxymannojirimycin (DMJNAc, 9), which was 
consistent with the previously reported data.14c, 23 The 
stereochemistry of 8 in C2-C3 (according to iminosugar 
nomenclature) was determined using NMR techniques. 
Coupling constant analysis of H3 showed an eq-eq (J= 2.0 
Hz) and ax-eq (J= 4.5 Hz) correlation consistent with an 
altro configuration. Further NOESY analysis of this 
compound corroborated this configuration by the absence of 
NoE between H3-H5 and allowed us to identify the 2-
acetamido-1,2-dideoxyaltronojirimycin as the major isomer 
(Figure 3).14e  
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Figure 3. Stereochemistry determination of 8. 
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In summary, here we synthetized both the manno and altro 
isomers of 2-acetamido-1,2-dideoxynojirimycin. Our 
procedure is based on the ring-opening of a sulphite with an 
azide that takes place with retention of configuration. We 
found that when the piperidine nitrogen is protected with an 
alkyl group such as benzyl, the nucleophilic ring-opening 
takes place with overall retention. Therefore, these results 
show the ability of the endocyclic amine to generate a 
putative aziridinium cation that can be attacked by the 
nucleophile. As the subsequent hydrolysis of the sulphite 
was not stereospecific, a substantial inversion of the 
secondary hydroxyl to obtain 14 was observed. It is known 
that the sulphite residual group can be hydrolysed both at 
the S-O or the C-O bond to afford two diastereomeric azido 
alcohols.24 Although, in general, only the first product was 
observed, in this particular case the resulting C-O cleaved 
bond product resulted to be the major isomer affording an 
inverted alcohol (Scheme 5).  
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Scheme 5. Stereochemical pathway leading to isomers 14 and 15. 
Conclusions 
A stereoselective synthesis of 2-acetamido-1,2-
dideoxyaltronojirimycin (8) and its manno epimer (9) has 
been described using Sharpless epoxidation as a source of 
chirality. This procedure completes an efficient 
stereodivergent approach to five isomers of 2-acetamido-
1,2-dideoxyiminosugars with high overall yields starting 
from the same key intermediate 7. The present approach is 
based on the stereoselective control of the sulphite ring-
opening with retention of configuration due to the 
anchimeric effect of the endocyclic amine. 
Experimental Section 
General considerations 
All reactions were performed in flame-dried glassware under 
nitrogen. Anhydrous solvents used were taken from a Solvent 
Purification System (Pure solve-MD-3; Innovative Technology, 
Inc.). All reagents were used as received. Optical rotations were 
measured at room temperature (23 ºC), and concentrations are 
reported in g/100 mL. 1H NMR spectra were obtained at 400 MHz 
with tetramethylsilane as internal standard. 13C NMR spectra were 
obtained at 100.6 MHz, and referenced to the solvent signal. 
Chemical shifts are recorded in ppm. Chromatographic separations 
were performed with SiO2 (70-230 mesh). 
 
(8S,8aR)-8-(Benzyloxy)-8,8a-dihydro-1H-oxazolo[3,4-a]pyridin-
3-one (10) 
To a stirred suspension of NaH (0.26 g, 10.83 mmol) in 10 mL 
of DMF at 0ºC was added via cannula a solution of compound 7 
(0.75 g, 4.82 mmol) in DMF (7 mL). After 10 min, benzyl bromide 
(0.61 mL, 5.06 mmol) was added via syringe and the temperature 
was left to warm to room temperature. After 4 h of vigorous 
stirring the crude was treated with water (10 mL), extracted with 
EtOAc (3x20 mL), dried over MgSO4 and concentrated under 
reduced pressure. The crude was purified by chromatography on 
silica gel using hexane/ethyl acetate and increasing polarity ratio to 
give 10 as a slight grey solid (1.21 g, 89%). 
[α]20D = +64.8 (c=1.8, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.41 – 7.29 (m, 5H), 5.97 (dd, J= 10.5, 1.5 Hz, 1H), 5.82 
(dd, J= 10.5, 2.5 Hz, 1H), 4.73 (d, J= 11.5 Hz, 1H), 4.52 (d, J= 
11.5 Hz, 1H),  4.46 (dd, J= 9.0, 8.0 Hz, 1H), 4.15 – 4.06 (m, 2H), 
3.94 (m, 1H), 3.70 – 3.58 (m, 2H). 13C-NMR (100 MHz, CDCl3, 
δ/ppm): 157.1 (CO), 137.3 (C), 128.6 (CH), 128.2 (CH), 127.9 
(CH), 126.4 (CH), 124.8 (CH), 74.0 (CH), 71.1 (CH2), 67.4 (CH2), 
54.5 (CH), 40.9 (CH2). IR (film, νmax / cm-1): 3033, 2911, 1761, 
1478, 1454, 1420, 1389, 1204, 1082, 1030. EM (CI-NH3, m/z): 
246 (M+1, 64%), 263 (M+18, 100%). El. Anal. Calcd. for 
C14H15NO3: C, 68.56%; H, 6.16%; N, 5.71%; found C, 68.85%; H, 
6.01%; N, 5.64% 
 
(2R,3S)-N-Benzyl-3-benzyloxy-2-benzyloxymethyl-1,2,3,6-
tetrahydropyridine (11)  
To a solution of 10 (0.17 g, 0.67 mmol) in MeOH : H2O 9:1 (7 mL) 
was added NaOH 6M (1.1 mL, 6.73 mmol) and the reaction was 
stirred at reflux during 16 h. The reaction was quenched with HCl 
1M until pH 8, extracted with EtOAc (3x 10 mL), washed with 
brine (1x 10 mL) and dried over MgSO4. Solvent was removed 
under low pressure obtaining a white solid, which was dissolved in 
DMF (4 mL) and added via cannula to a suspension of NaH (68 
mg, 2.69 mmol) in DMF (2 mL) cooled at 0ºC. After 10 min, 
benzyl bromide (0.21 mL, 6.73 mmol) was added and the reaction 
was allowed to stir at r.t. for 16h. H2O (10 mL) was added and the 
crude was extracted with EtOAc (3x 5 mL), dried over MgSO4 and 
purified on silica·Et3N (2,5% v/v) using hexane/EtOAc to give 11 
(0.23 mg, 87%) as a yellow oil.  
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[α]20D = +12.7 (c=0.2, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.42 – 7.20 (m, 15H), 5.86 (m, 2H), 4.53 (s, 2H), 4.46 (s, 
2H), 3.97 (m, 2H), 3.77 (d, J = 14.5 Hz), 3.75 (dd, J = 10.0, 5.0 Hz, 
1H), 3.50 (dd, J = 10.0, 6.0 Hz, 1H), 3.17 (dd, J = 10.0, 5.0 Hz, 
1H), 3.08 (s, 2H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  139.2 
(C), 138.8 (C), 138.3 (C), 129.4 (CH), 128.9 (CH), 128.3 (CH), 
128.2 (CH), 128.2 (CH), 127.9 (CH), 127.6 (CH), 127.4 (CH), 
126.9 (CH), 124.1 (CH), 73.2 (CH2), 72.3 (CH), 70.5 (CH2), 66.5 
(CH2), 59.3 (CH), 58.2 (CH2), 48.8 (CH2). IR (film, νmax / cm-1): 
3028, 2857, 1494, 1452, 1098, 1069, 735, 696 HRMS (ES):  
Calcd. for C27H30NO2 : 400.22711, found 400.22695 
 
4,6-Di-O-benzyl-5-N-Benzyl-1-deoxymannojirimycin (12)  
(DHQD)2Phal (21 mg, 0.03 mmol), K2OsO4 (6 mg, 0.01 mmol), 
K2CO3 (135 mg, 0.97 mmol), and K3[Fe(CN)6] (322 mg, 0.97 
mmol) were dissolved in ACN:H2O 1:1 (4 mL). The reaction was 
cooled to 0 ºC and CH3SO2NH2 (32 mg, 0.32 mmol) was then 
added. After 10 min, a solution of 13 (0.13 g, 0.32 mmol) in 
ACN:H2O 1:1 (2 mL) was added and the mixture was left to warm 
to r.t. and stirred until no starting material was observed by TLC. 
The reaction was treated with Na2SO3 (200 mg) and stirred for 1h. 
It was then extracted with EtOAc (3x 10mL) and the organic phase 
was washed with brine (1x 10mL), dried over MgSO4, and purified 
on silica·Et3N (2,5% v/v) using hexane/EtOAc to give 12  (72 mg, 
48%)  as one diastereomer as a yellow oil. 
[α]20D = -7.2 (c=0.15, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.34 – 7.24 (m, 15H), 4.90 (d, J = 11.0 Hz, 1H), 4.56 (d, J 
= 11.0 Hz, 1H), 4.46 (s, 2H), 4.17 (d, J = 13.0 Hz, 1H), 3.83 (dd, J 
= 10.5, 2.5 Hz, 1H), 3.76 (dd, J = 10.5, 3.0 Hz, 2H), 3.64 (t, J = 8.5 
Hz, 1H), 3.57 (dd, J = 8.5, 3.0 Hz, 1H), 3.27 (d, J = 12.5 Hz, 1H), 
2.91 (dd, J = 12.5, 4.5 Hz, 1H), 2.38 (dt, J = 8.5, 2.5 Hz, 1H), 2.22 
(dd, J = 12.5, 1.5 Hz, 1H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  
138.6 (C), 138.5 (C), 137.8 (C), 128.9 (CH), 128.4 (CH), 128.4 
(CH), 128.0 (CH), 128.0 (CH), 127.8 (CH), 127.7 (CH), 127.2 
(CH), 78.4 (CH), 75.9 (CH), 74.7 (CH2), 73.3 (CH2), 68.1 (CH), 
66.8 (CH2), 64.8 (CH), 56.6 (CH2), 54.7 (CH2). IR (film, νmax / cm-
1): 3406, 2911, 2859, 1452, 1097, 1066, 734, 697. HRMS (ES):  
Calcd. for C27H32NO4 : 434.23259, found 434.23314 
 
2-Azido-4,6-di-O-benzyl-5-N-benzyl-1,2-
dideoxyaltronojirimycin (14) and 2-Azido-4,6-di-O-benzyl-5-N-
benzyl-1,2-dideoxymannojirimycin (15) 
(DHQD)2Phal (0.12 g, 0.15 mmol), K2OsO4 (27 mg, 0.07 mmol), 
K2CO3 (882 mg, 6.38 mmol) and K3[Fe(CN)6] (2.1 g, 6.38 mmol) 
were dissolved in ACN:H2O 1:1 (15 mL). The reaction was cooled 
to 0 ºC and CH3SO2NH2 (208 mg, 2.11 mmol) was then added. 
After 10 min, a solution of 13 (0.84 g, 2.11 mmol) in ACN:H2O 
1:1 (6 mL) was added and the mixture was left to warm to r.t. and 
stirred until no starting material was observed by TLC. The 
reaction was treated with Na2SO3 (3 g) and stirred for 1h. The 
crude was extracted with EtOAc (3x 30 mL) and the organic phase 
was washed with brine (1x 10 mL) and dried over MgSO4. The 
resulting oil was redissolved in CH2Cl2 (35 mL) and cooled at 0ºC. 
TEA (1.23 mL, 8.84 mmol) was added followed by dropwise 
addition of SOCl2 (490 µL, 7.58 mmol). The reaction was stirred at 
0ºC for 1h. H2O (30 mL) was added and the crude was extracted 
with CH2Cl2 (3x 20 mL). The resulting orange oil was redissolved 
in acetone:water 2:1 (66 mL) and NaN3 (164 mg, 2.52 mmol) was 
added. The mixture was stirred at 35ºC overnight. Solvents were 
removed under low pressure and the resulting aqueous phase was 
extracted with EtOAc (3x 30 mL), dried over MgSO4 and purified 
on silica·Et3N (2,5% v/v) using hexane/EtOAc to give give 16 
(0.34 g, 35%) as a colorless oil and 17 (110 mg, 11%) as a 
colorless oil. 
[α]20D = +35.0 (c=0.80, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.37 – 7.21 (m, 15H), 4.60 (d, J = 12.0 Hz, 1H), 4.50 (d, J 
= 12.0 Hz, 1H), 4.44 (d, J = 12.0 Hz, 1H), 4.39 (d, J = 12.0 Hz, 
1H), 4.10 (dd, J = 11.0, 4.0 Hz, 1H), 3.97 (d, J = 14.0 Hz, 1H), 
3.89 (d, J = 11.5 Hz, 1H), 3.81 (s, 1H), 3.71 (d, J = 14.0 Hz, 1H), 
3.60 (dd, J = 11.5, 8.5 Hz, 1H), 3.32 (dd, J = 10.5, 3.0 Hz, 1H), 
3.27 – 3.16 (m, 2H), 3.08 – 3.01 (m, 2H). 13C-NMR (100 MHz, 
CDCl3, δ/ppm):  139.6 (C), 137.9 (C), 137.2 (C),  128.5 (CH), 
128.5 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 127.8 (CH), 
127.7 (CH), 127.5 (CH), 127.2 (CH), 86.0 (CH), 73.7 (CH2), 73.6 
(CH), 71.32 (CH2), 71.0 (CH), 70.8 (CH2), 67.1 (CH), 58.6 (CH2), 
50.2 (CH2).  IR (film, νmax / cm-1): 3410, 2930, 2859, 2099, 1453, 
1090, 1021. HRMS (ES):  Calcd. for C27H31N4O3 : 459.23907, 
found 459.23863 
[α]20D = -19.3 (c=0.75, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.37 – 7.22 (m, 15H), 4.68 (d, J = 11.5 Hz, 1H), 4.57 (d, J 
= 11.5 Hz, 1H), 4.50 (s, 2H), 4.10 (d, J = 13.5 Hz, 1H), 3.80 (m, 
3H), 3.71 (m, 2H), 3.86 – 3.66 (m, 5H), 3.46 (d, J = 13.5 Hz, 1H), 
3.03 (dd, J = 12.5, 5.5 Hz, 1H), 2.78 (br, 1H), 2.61 (m, 1H), 2.37 
(dd, J = 12.5, 2.5 Hz, 1H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  
138.6 (C), 138.1 (C), 137.7 (C), 128.7 (CH), 128.5 (CH), 128.4 
(CH), 128.3 (CH), 127.9 (CH), 127.8 (CH), 127.8 (CH), 127.7 
(CH), 127.0 (CH), 78.3 (CH), 73.9 (CH2), 73.3 (CH2), 73.2 (CH), 
67.7 (CH2), 62.8 (CH), 59.0 (CH), 57.6 (CH2), 50.6 (CH2). IR 
(film, νmax / cm-1): 3423, 2917, 2099, 1452, 1270, 1097, 1027. 
HRMS (ES):  Calcd. for C27H31N4O3 : 459.23907, found 
459.23833 
 
 
2-Azido-3,4,6-tri-O-benzyl-5-N-benzyl-1,2-
dideoxyaltronojirimycin (16)  
To a suspension of NaH (27 mg, 1.05 mmol) in DMF (1 mL) 
cooled at 0ºC was added via cannula a solution of 16 (161 mg, 0.35 
mmol) in DMF (4 mL). After 10 min, benzyl bromide (64 µL, 0.52 
mmol) was added dropwise and the reaction was allowed to stir at 
r.t. until no starting material was observed by TLC.  Then, H2O (5 
mL) was added and the reaction was extracted with CH2Cl2 (3x 5 
mL), dried over MgSO4 and purified by chromatography on silica 
gel using hexane/EtOAc to give 16 (172 mg, 89%) as a colorless 
oil. 
 [α]20D = +10.5 (c=1.55, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.35 – 7.15 (m, 20H), 4.57 (d, J = 12.0 Hz, 1H), 4.52 (d, J 
= 12.0 Hz, 1H), 4.45 (d, J = 11.5 Hz, 1H), 4.40 (d, J = 11.5 Hz, 
1H), 4.37 (d, J = 12.0 Hz, 1H), 4.28 (d, J = 12.0 Hz, 1H), 4.00 – 
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3.96 (m, 2H), 3.89 (d, J = 13.5 Hz, 1H), 3.83 (d, J = 13.5 Hz, 1H), 
3.44 (dd, J = 11.5, 8.5 Hz, 1H), 3.37 (m, 1H), 3.25 (m, 1H), 3.20 – 
3.12 (m, 3H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  139.3 (C), 
138.4 (C), 138.2 (C), 137.8 (C), 129.00 (CH), 128.3 (CH), 128.3 
(CH), 128.2 (CH), 128.2 (CH), 127.9 (CH), 127.7 (CH), 127.6 
(CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 127.2 (CH), 82.5 (CH), 
82.0 (CH), 72.9 (CH2), 71.9 (CH2), 71.8 (CH2), 71.1 (CH2), 68.9 
(CH), 65.9 (CH), 59.9 (CH2), 50.4 (CH2). IR (film, νmax / cm-1): 
2923, 2861, 2099, 1453, 1093, 1059. HRMS (ES): Calcd. for 
C34H37N4O3 : 549.28602, found 549.28552 
 
2-Acetamido-3,4,6-tri-O-benzyl-5-N-benzyl-1,2-
dideoxyaltronojirimycin (17) 
To a solution of 16 (133 mg, 0.24 mmol) in EtOAc (5 mL) was 
added Pd/C (13 mg, 0.01 mmol) and was charged with H2 (5 barg) 
and stirred at r.t. for 20h. Palladium was filtered over Celite 
washing with MeOH and solvents were removed under low 
presure. The obtained colorless oil was redisolved in pyridine (2 
mL) and Ac2O (48 μL, 0.39 mmol) was added. The reaction was 
stirred at 40ºC for 16h. Then, H2O (5 mL) was added and the 
reaction was extracted with EtOAc (3x 5 mL), dried over MgSO4 
and purified by chromatography on silica gel using hexane/EtOAc 
to give 17 (110 mg, 80%) as a slightly yellow oil. 
 [α]20D = +24.8 (c=1.21, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.38 – 7.20 (m, 20H), 5.81 (t, J = 5.0 Hz, 1H), 4.58 (d, J = 
12.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H), 
4.40 (d, J = 12.0 Hz, 1H), 4.32 (d, J = 12.0  Hz, 1H), 4.29 (d, J = 
12.0 Hz, 2H), 3.98 (t, J = 3.5Hz, 1H), 3.89 (m, 2H), 3.72 (d, J = 
13.5 Hz, 1H), 3.42 (ddd, J = 13.5, 5.5, 3.5 Hz, 1H), 3.35 (dd, J = 
9.5, 7.5 Hz, 1H), 3.28 (m, 1H), 3.19 (m, 2H), 3.09 (m, 1H), 1.62 (s, 
3H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  169.7 (CO), 138.9 (C), 
138.3 (C), 138.2 (C), 137.8 (C), 129.2 (CH), 128.6 (CH), 128.3 
(CH), 128.3 (CH), 128.3 (CH), 128.1 (CH), 128.0 (CH), 127.7 
(CH), 127.7 (CH), 127.6 (CH), 127.6 (CH), 127.2 (CH), 83.1 (CH), 
81.7 (CH), 73.0 (CH2), 71.7 (CH2), 71.3 (CH2), 70.7 (CH2), 67.9 
(CH), 63.4 (CH), 58.5 (CH2), 38.0 (CH2), 23.0 (CH3). IR (film, 
νmax / cm-1): 3295, 2861, 1652, 1453, 1098, 1066, 735, 697. HRMS 
(ES):  Calcd. for C36H41N2O4 : 565.30608, found 565.30538 
 
2-Acetamido-1,2-dideoxyaltronojirimycin (8) 
To a solution of  19 (74 mg, 0.13 mmol) in HCl 1,25 M MeOH (3 
mL) was added Pd/C (12 mg, 0.01 mmol) and the reaction was 
charged with H2 (5 barg) and stirred at r.t. for 20h. Palladium was 
filtered over Celite washing with MeOH and solvents were 
removed under low presure. The crude was purified by 
chromatography on silica gel using CH2Cl2/MeOH/NH3 90:8:2 to 
give 8 (23 mg, 85%) as a colorless oil. 
[α]20D = +11.7 (c=0.55, H2O). 1H-NMR (400 MHz, D2O, δ/ppm): 
4.04 (dd, J = 4.5, 2.5 Hz, 1H), 3.89 (dd, J = 5.0, 2.5 Hz, 1H), 3.73 
(dd, J = 12.0, 6.0 Hz, 1H), 3.66 (dd, J = 12.0, 6.0 Hz, 1H), 3.45 (m, 
1H), 3.32 – 3.24 (m, 2H), 3.01 (m, 1H), 2.02 (s, 3H). 13C-NMR 
(100 MHz, D2O, δ/ppm, TFA internal reference):  174.4 (CO), 79.1 
(CH), 77.3 (CH), 65.2 (CH), 642.0 (CH2), 59.3 (CH), 38.6 (CH2), 
21.8 (CH3).  IR (film, νmax / cm-1): 3212, 3051, 2894, 1661, 1437, 
1200, 1130. HRMS (ES):  Calcd. for C8H17N2O4 : 205.11828, 
found 205.11812 
 
2-Azido-3,4,6-tri-O-benzyl-5-N-benzyl-1,2-
dideoxymannojirimycin (18)  
To a suspension of NaH (17 mg, 0.67 mmol) in DMF (1 mL) 
cooled at 0ºC was added via cannula a solution of 17 (102 mg, 0.22 
mmol) in DMF (4 mL). After 10 min, benzyl bromide (41 µL, 0.34 
mmol) was added dropwise and the reaction was allowed to stir at 
r.t. until no starting material was observed by TLC.  Then, H2O (5 
mL) was added and the reaction was extracted with CH2Cl2 (3x 5 
mL), dried over MgSO4 and purified by chromatography on 
silica·Et3N (2,5% v/v) using hexane/EtOAc to give 18 (90 mg, 
74%)  as a slightly yellow oil.  
[α]20D = -30.1 (c=0.59, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.38 – 7.17 (m, 20H), 4.77 (d, J = 11.0 Hz, 1H), 4.67 (d, J 
= 11.5 Hz, 1H), 4.61 (d, J = 11.5 Hz, 1H), 4.52 (d, J = 11.0 Hz, 
1H), 4.43 (s, 2H), 4.12 (d, J = 13.5 Hz, 1H), 3.86 (t, J = 7.5 Hz, 
1H), 3.77 (m, 2H), 3.74 (dt, J = 5.5, 3.0 Hz, 1H), 3.64 (dd, J = 7.5, 
3.5 Hz, 1H), 3.49 (d, J = 13.5 Hz, 1H), 2.96 (dd, J = 12.5, 5.5 Hz, 
1H), 2.65 (m, 1H), 2.27 (dd, J = 12.5, 3.0 Hz, 1H). 13C-NMR (100 
MHz, CDCl3, δ/ppm): 138.7 (C), 138.3 (C), 138.2 (C), 137.8 (C), 
128.7 (CH), 128.7 (CH), 128.4 (CH), 128.3 (CH), 128.3 (CH), 
128.2 (CH), 128.2 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH), 
127.6 (CH), 127.5 (CH), 126.9 (CH), 81.6 (CH), 75.4 (CH), 74.2 
(CH2), 73.0 (CH2), 72.3 (CH2), 67.6 (CH2), 63.4 (CH), 57.7 (CH2), 
56.7 (CH), 50.6 (CH2). IR (film, νmax / cm-1): 2853, 2096, 1452, 
1102, 1066. HRMS (ES):  Calcd. for C34H37N4O3 : 549.2860, 
found 549.2855 
 
2-Acetamido-3,4,6-tri-O-benzyl-5-N-benzyl-1,2-
dideoxymannojirimycin (19)  
To a a solution of 18 (90 mg, 0.16 mmol) in EtOAc (4 mL) was 
added Pd/C (17 mg, 0.01 mmol) and the reaction was charged with 
H2 (5 barg) and stirred at r.t. for 20h. Palladium was filtered over 
Celite washing with MeOH and solvents were removed under low 
presure. The obtained colorless oil was redisolved in pyridine (2 
mL) and Ac2O (24 μL, 0.23 mmol) was added. The reaction was 
stirred at r.t. for 16h. Then, H2O (5 mL) was added and the reaction 
was extracted with EtOAc (3x 5 mL), dried over MgSO4 and 
purified on silica·Et3N (2,5% v/v) using hexane/EtOAc to give 19  
(74 mg, 80%)  as a slightly yellow oil.  
[α]20D = -8.1 (c=0.79, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.37 – 7.20 (m, 20H), 6.19 (d, J = 9.5 Hz, 1H), 4.90 (d, J = 
11.0 Hz, 1H), 4.78 (d, J = 11.0 Hz, 1H), 4.53 (m, 1H), 4.47 (d, J = 
11.0 Hz, 1H), 4.46 (d, J = 12.0 Hz, 1H), 4.42 (d, J = 12.0 Hz, 1H), 
4.14 (d, J = 13.5 Hz, 1H), 3.81 (m, 2H), 3.71 (t, J = 8.5 Hz, 1H), 
3.55 (dd, J = 8.5, 4.5 Hz, 1H), 3.29 (d, J = 13.5 Hz, 1H), 2.72 (dd, 
J = 12.0, 4.5 Hz, 1H), 2.47 (dt, J = 8.5, 3.0 Hz, 1H), 2.22 (dd, J = 
12.0, 2.0 Hz, 1H), 1.93 (s, 3H). 13C-NMR (100 MHz, CDCl3, 
δ/ppm):  169.8 (CO), 138.7 (C) , 138.5 (C), 138.1 (C), 137.9 (C), 
128.9 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 128.3 (CH), 
128.3 (CH), 127.9 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 
127.5 (CH), 127.1 (CH), 81.7 (CH), 77.0 (CH), 74.8 (CH2), 73.3 
FULL PAPER    
 
 
 
 
 
(CH2), 71.1 (CH2), 66.5 (CH2), 64.5 (CH), 56.7 (CH2), 52.8 (CH2), 
44.3 (CH), 23.5 (CH3). IR (film, νmax / cm-1): 2860, 1674, 1496, 
1452, 1011. HRMS (ES):  Calcd. for C36H40N2O4 : 565.3061, 
found 565.3050 
 
2-Acetamido-1,2-dideoxymannojirimycin (9)  
A solution of  19 (20 mg, 0.04 mmol) in HCl 1,25 M MeOH (3 
mL) was added Pd/C (espatula tip) and was charged with H2 (5 
barg) and stirred at r.t. for 20h. Palladium was filtered over Celite 
washing with MeOH and solvents were removed under low 
presure. The crude was purified by chromatography on silica gel 
using CH2Cl2/MeOH/NH3 90:8:2 to give 9 (7 mg, 95%) as a white 
solid. Spectroscopic data were consistent with previously reported 
data.23 
1H-NMR (400 MHz, CD3OD, δ/ppm): 4.50 (s, 1H), 3.82 (dd, J = 
11.0, 3.0 Hz, 1H), 3.72 (dd, J = 11.0, 5.5 Hz, 1H), 3.60 (dd, J = 
9.5, 4.5 Hz, 1H), 3.45 (t, J = 9.5 Hz, 1H), 3.00 (dd, J = 13.0, 3.0 
Hz, 1H), 2.79 (dd, J = 13.0, 2.5 Hz, 1H), 2.47 (ddd, J = 9.5, 5.5, 
3.0 Hz, 1H), 2.04 (s, 3H). HRMS (ES):  Calcd. for C8H17N2O4 : 
205.11828, found 205.11830. 
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The altro and manno isomers (8 and 9) of 2-acetamido-1,2-dideoxynojirimycin have been synthetized 
from the key intermediate 7. The key step was the stereoselective sulphite ring-opening with retention 
of configuration due to the anchimeric effect of the endocyclic amine. 
 
